Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell–derived cortical interneurons from subjects with schizophrenia

Nature Neuroscience

Volumn 22, Issue 2, 2019, Pages 229-242

  Shao, Zhicheng ^a,b   Noh, Haneul ^a,c   Bin Kim, Woong ^d   Ni, Peiyan ^a,c   Nguyen, Christine ^a   Cote, Sarah E ^a   Noyes, Elizabeth ^a   Zhao, Joyce ^a   Parsons, Teagan ^a   Park, James M ^c   Zheng, Kelvin ^c   Park, Joshua J ^c   Coyle, Joseph T ^a   Weinberger, Daniel R ^e   Straub, Richard E ^e   Berman, Karen F ^f   Apud, Jose ^f   Ongur, Dost ^a   Cohen, Bruce M ^a   McPhie, Donna L ^a   Rapoport, Judith L ^f   Perlis, Roy H ^g   Lanz, Thomas A ^h   Xi, Hualin Simon ^h   Yin, Changhong ^c   Huang, Weihua ^c   Hirayama, Teruyoshi ^i,k   Fukuda, Emi ⁱ   Yagi, Takeshi ⁱ   Ghosh, Sulagna ^j   Eggan, Kevin C ^j   Kim, Hae Young ^c   Eisenberg, Leonard M ^c   Moghadam, Alexander A ^c   Stanton, Patric K ^c   Cho, Jun Hyeong ^d   Chung, Sangmi ^a,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b XIAMEN UNIVERSITY   (China)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h PFIZER INC   (United States)

ⁱ OSAKA UNIVERSITY   (Japan)

^j Harvard University   (United States)

^k UNIVERSITY OF TOKUSHIMA   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CADHERIN; PROTEIN KINASE C; PROTOCADHERIN; UNCLASSIFIED DRUG; PCDH1 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL INTERNEURON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; INTERNEURON; MALE; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPSE; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CADHERINS; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERNEURONS; MALE; MICE; MICE, KNOCKOUT; PREFRONTAL CORTEX; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 85060492176     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/s41593-018-0313-z     Document Type: Article

References (61)

1. Sullivan, P. F., Kendler, K. S. & Neale, M. C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60, 1187–1192 (2003)
2. Weinberger, D. R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660–669 (1987)
3. Buchanan, R. W. & Carpenter, W. T. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J. Nerv. Ment. Dis. 182, 193–204 (1994)
4. Elvevåg, B. & Goldberg, T. E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1–21 (2000)
5. Ripke, S. et al. Schizophrenia working group of the psychiatric genomics consortium. biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014)
6. Fromer, M. et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat. Neurosci. 19, 1442–1453 (2016)
7. Sekar, A. et al. Schizophrenia risk from complex variation of complement component 4. Nature 530, 177–183 (2016)
8. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006)
9. Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221–225 (2011)
10. Noh, H., Shao, Z., Coyle, J. T. & Chung, S. Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2382–2387 (2017)
11. Benes, F. M. The GABA system in schizophrenia: cells, molecules and microcircuitry. Schizophr. Res. 167, 1–3 (2015)
12. Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312–324 (2005)
13. Volk, D. W. & Lewis, D. A. Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia. Schizophr. Bull. 40, 952–957 (2014)
14. Lewis, D. A. et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165, 1585–1593 (2008)
15. Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 13, 76–83 (2010)
16. Warren, L., Ni, Y., Wang, J. & Guo, X. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci. Rep. 2, 657 (2012)
17. Kim, T. G. et al. Efficient specification of interneurons from human pluripotent stem cells by dorsoventral and rostrocaudal modulation. Stem Cells 32, 1789–1804 (2014)
18. Ma, T. et al. Subcortical origins of human and monkey neocortical interneurons. Nat. Neurosci. 16, 1588–1597 (2013)
19. Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785–798 (2013)
20. Hasegawa, S. et al. Distinct and cooperative functions for the Protocadherin-α, -β and -γ clusters in neuronal survival and axon targeting. Front. Mol. Neurosci. 9, 155 (2016)
21. Hirayama, T. & Yagi, T. Clustered protocadherins and neuronal diversity. Prog. Mol. Biol. Transl. Sci. 116, 145–167 (2013)
22. Swerdlow, N. R. et al. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 63, 1325–1335 (2006)
23. Katori, S. et al. Protocadherin-alpha family is required for serotonergic projections to appropriately innervate target brain areas. J. Neurosci. 29, 9137–9147 (2009)
24. Fukuda, E. et al. Down-regulation of protocadherin-alpha A isoforms in mice changes contextual fear conditioning and spatial working memory. Eur. J. Neurosci. 28, 1362–1376 (2008)
25. Garrett, A. M., Schreiner, D., Lobas, M. A. & Weiner, J. A. γ-protocadherins control cortical dendrite arborization by regulating the activity of a FAK/PKC/MARCKS signaling pathway. Neuron 74, 269–276 (2012)
26. Southwell, D. G. et al. Interneurons from embryonic development to cell-based therapy. Science 344, 1240622 (2014)
27. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014)
28. Mayer, C. et al. Developmental diversification of cortical inhibitory interneurons. Nature 555, 457–462 (2018)
29. Phillips, G. R. et al. Gamma-protocadherins are targeted to subsets of synapses and intracellular organelles in neurons. J. Neurosci. 23, 5096–5104 (2003)
30. Wang, X. et al. Gamma protocadherins are required for survival of spinal interneurons. Neuron 36, 843–854 (2002)
31. Bonn, S., Seeburg, P. H. & Schwarz, M. K. Combinatorial expression of alpha- and gamma-protocadherins alters their presenilin-dependent processing. Mol. Cell. Biol. 27, 4121–4132 (2007)
32. Murata, Y., Hamada, S., Morishita, H., Mutoh, T. & Yagi, T. Interaction with protocadherin-gamma regulates the cell surface expression of protocadherin-alpha. J. Biol. Chem. 279, 49508–49516 (2004)
33. Chen, J. et al. alpha- and gamma-Protocadherins negatively regulate PYK2. J. Biol. Chem. 284, 2880–2890 (2009)
34. Lu, W. C. et al. The protocadherin alpha cluster is required for axon extension and myelination in the developing central nervous system. Neural Regen. Res. 13, 427–433 (2018)
35. Morishita, H. et al. Myelination triggers local loss of axonal CNR/protocadherin alpha family protein expression. Eur. J. Neurosci. 20, 2843–2847 (2004)
36. Kohmura, N. et al. Diversity revealed by a novel family of cadherins expressed in neurons at a synaptic complex. Neuron 20, 1137–1151 (1998)
37. Hirayama, T. & Yagi, T. Regulation of clustered protocadherin genes in individual neurons. Semin. Cell. Dev. Biol. 69, 122–130 (2017)
38. Jones, C. A., Watson, D. J. & Fone, K. C. Animal models of schizophrenia. Br. J. Pharmacol. 164, 1162–1194 (2011)
39. Pak, C. et al. Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell 17, 316–328 (2015)
40. Southwell, D. G. et al. Intrinsically determined cell death of developing cortical interneurons. Nature 491, 109–113 (2012)
41. Franco, R. & Cedazo-Minguez, A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front. Pharmacol. 5, 146 (2014)
42. Thomsen, M. S., Hansen, H. H., Timmerman, D. B. & Mikkelsen, J. D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16, 323–343 (2010)
43. Amrollahi, Z. et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J. Affect Disord. 129, 327–331 (2011)
44. Bebchuk, J. M. et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57, 95–97 (2000)
45. Yildiz, A., Guleryuz, S., Ankerst, D. P., Ongür, D. & Renshaw, P. F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 65, 255–263 (2008)
46. Forstner, A. J. et al. Identification of shared risk loci and pathways for bipolar disorder and schizophrenia. PLoS One 12, e0171595 (2017)
47. Chung, D. W., Fish, K. N. & Lewis, D. A. Pathological basis for deficient excitatory drive to cortical parvalbumin interneurons in schizophrenia. Am. J. Psychiatry 173, 1131–1139 (2016)
48. Roberts, R. C., Barksdale, K. A., Roche, J. K. & Lahti, A. C. Decreased synaptic and mitochondrial density in the postmortem anterior cingulate cortex in schizophrenia. Schizophr. Res. 168, 543–553 (2015)
49. Akbarian, S. & Huang, H. S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain. Res. Rev. 52, 293–304 (2006)
50. Bliss, L. A. et al. Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PLoS One 7, e45282 (2012)
51. Cho, J. H., Deisseroth, K. & Bolshakov, V. Y. Synaptic encoding of fear extinction in mPFC-amygdala circuits. Neuron 80, 1491–1507 (2013)
52. Zhao, S. et al. QuickRNASeq lifts large-scale RNA-seq data analyses to the next level of automation and interactive visualization. BMC Genomics 17, 39 (2016)
53. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527 (2016)
54. Scharpf, R. B., Irizarry, R. A., Ritchie, M. E., Carvalho, B. & Ruczinski, I. Using the R package crlmm for genotyping and copy number estimation. J. Stat. Softw. 40, 1–32 (2011)
55. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009)
56. Delaneau, O., Coulonges, C. & Zagury, J. F. Shape-IT: new rapid and accurate algorithm for haplotype inference. BMC Bioinformatics 9, 540 (2008)
57. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007)
58. Hasegawa, S. et al. The protocadherin-alpha family is involved in axonal coalescence of olfactory sensory neurons into glomeruli of the olfactory bulb in mouse. Mol. Cell. Neurosci. 38, 66–79 (2008)
59. Herring, A. H. Applied Longitudinal Analysis, 2nd Edition, by Garrett M. Fitzmaurice, Nan M. Laird, and James H. Ware, John Wiley & Sons, 2011. J. Biopharm. Stat. 23, 940–941 (2013)
60. Laird, N. M. & Ware, J. H. Random-effects models for longitudinal data. Biometrics 38, 963–974 (1982)
61. Topol, A. et al. Dysregulation of miRNA-9 in a subset of schizophrenia patient-derived neural progenitor cells. Cell Rep. 15, 1024–1036 (2016)